BioMarin Pharmaceutical Inc. Share Price

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
84.09 USD +0.90% Intraday chart for BioMarin Pharmaceutical Inc. -1.09% -12.79%
Sales 2024 * 2.74B 212B Sales 2025 * 3.09B 239B Capitalization 15.97B 1,235B
Net income 2024 * 363M 28.07B Net income 2025 * 523M 40.45B EV / Sales 2024 * 5.57 x
Net cash position 2024 * 698M 54.01B Net cash position 2025 * 1.34B 103B EV / Sales 2025 * 4.74 x
P/E ratio 2024 *
45.6 x
P/E ratio 2025 *
31.2 x
Employees 3,401
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Estimated data
Dynamic Chart
1 day+0.90%
1 week-1.09%
Current month+2.14%
1 month+0.37%
3 months-5.12%
6 months-8.85%
Current year-12.79%
More quotes
1 week
83.11
Extreme 83.11
86.24
1 month
80.53
Extreme 80.53
86.24
Current year
73.68
Extreme 73.675
99.25
1 year
73.68
Extreme 73.675
99.56
3 years
70.73
Extreme 70.73
117.77
5 years
62.88
Extreme 62.88
131.95
10 years
59.10
Extreme 59.1
151.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 11-30
Director of Finance/CFO 50 30/11/02
Chief Tech/Sci/R&D Officer 62 30/04/20
Members of the board TitleAgeSince
Director/Board Member 70 03/01/16
Chairman 65 13/12/06
Director/Board Member 76 30/06/02
More insiders
Date Price Change Volume
19/07/24 84.09 +0.90% 1,883,904
18/07/24 83.34 -1.56% 1,312,663
17/07/24 84.66 -1.43% 1,076,865
16/07/24 85.89 +1.54% 1,098,454
15/07/24 84.59 -0.51% 1,082,229

Delayed Quote Nasdaq, July 19, 2024 at 09:00 pm

More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
84.09 USD
Average target price
109.4 USD
Spread / Average Target
+30.12%
Consensus